Leiden/Amsterdam Center for Drug Research (LACDR), Division of Medicinal Chemistry, Department of Pharmacochemistry, Faculty of Exact Sciences, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands.
Drug Discov Today. 2009 Jul;14(13-14):630-46. doi: 10.1016/j.drudis.2009.03.009. Epub 2009 Mar 31.
Fragment-based drug discovery (FBDD) represents a logical and efficient approach to lead discovery and optimisation. It can draw on structural, biophysical and biochemical data, incorporating a wide range of inputs, from precise mode-of-binding information on specific fragments to wider ranging pharmacophoric screening surveys using traditional HTS approaches. It is truly an enabling technology for the imaginative medicinal chemist. In this review, we analyse a representative set of 23 published FBDD studies that describe how low molecular weight fragments are being identified and efficiently transformed into higher molecular weight drug candidates. FBDD is now becoming warmly endorsed by industry as well as academia and the focus on small interacting molecules is making a big scientific impact.
基于片段的药物发现（FBDD）代表了一种合理且高效的先导物发现和优化方法。它可以利用结构、生物物理和生化数据，结合广泛的输入信息，从特定片段的精确结合模式信息到使用传统高通量筛选方法进行更广泛的药效团筛选调查。它确实是富有想象力的药物化学家的一项使能技术。在这篇综述中，我们分析了 23 篇已发表的 FBDD 研究的代表性集合，这些研究描述了如何鉴定低分子量片段并将其有效地转化为更高分子量的药物候选物。FBDD 现在受到工业界和学术界的热烈支持，而对小分子相互作用的关注正在产生重大的科学影响。
